About Tergene Biotech
Tergene Biotech is a company based in Hyderabad (India) founded in 2008 was acquired by Aurobindo Pharma in February 2025. Tergene Biotech operates in a competitive market with competitors including Biological E, Insmed, Affinivax, Altimmune and Eligo Bioscience, among others.
- Headquarter Hyderabad, India
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Tergene Biotech Limited
- Date of Incorporation 07 Mar, 2008
- Jurisdiction Hyderabad, Telangana, India
-
Annual Revenue
$778.5 K (USD)107.03as on Mar 31, 2023
-
Net Profit
-$659.37 K (USD)20.31as on Mar 31, 2023
-
EBITDA
-$1.02 M (USD)-43.79as on Mar 31, 2023
-
Latest Funding Round
Not available
-
Investors
Aurobindo Pharma
& 2 more
-
Employee Count
Not available
-
Acquired by
Aurobindo Pharma
(Feb 26, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Tergene Biotech
Investors in Tergene Biotech
Tergene Biotech has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Aurobindo Pharma, Department of Biotechnology and BIRAC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Business incubation services are provided across multiple sectors.
|
Locked | Locked | Locked | |
|
Biotechnology research, guidelines, and funding by the Government of India.
|
Locked | Locked | Locked | |
|
Generic biocatalytic solutions are provided for pharmaceutical applications.
|
Locked | Locked | Locked |
Investor details for Tergene Biotech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tergene Biotech
Investment portfolio details for Tergene Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Tergene Biotech
Detailed financials for Tergene Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tergene Biotech Comparisons
Peer comparison for Tergene Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Tergene Biotech
Tergene Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biological E, Insmed, Affinivax, Altimmune and Eligo Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| Locked | Locked | Locked |
Developer of small molecule inhibitors for rare lung diseases
|
|
| Locked | Locked | Locked |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| Locked | Locked | Locked |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for treating multiple infectious diseases
|
Detailed competitors of Tergene Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tergene Biotech
Complete news archive for Tergene Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tergene Biotech
Tergene Biotech was founded in 2008 and raised its 1st funding round 4 years after it was founded.
Tergene Biotech is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Annual revenue of Tergene Biotech is $778.5K as on Mar 31, 2023.
Tergene is developing bio-conjugate platform technologies for novel vaccines and antibody drug conjugates. It has developed technologies for the production of various vaccines and biosimilars such as Acellular Pertussis (ACP) vaccine, Haemophilus influenza type B (HiB) conjugated vaccine, Typhoid Vaccine, Streptokinase, Terinase - a thrombolytic enzyme are some of its developed technologies. The vaccines are currently under advanced stage of development include a multivalent pneumococcal vaccine and Meningococcal vaccine. It also offers a full range of contract research services from bioprocess development to manufacturing to approval of the finished product.
Tergene Biotech's top competitors include Biological E, Insmed and Vaxart.
Tergene Biotech has 3 investors. Key investors include Aurobindo Pharma, Department of Biotechnology, and BIRAC.